search
Back to results

Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 1
Locations
Spain
Study Type
Interventional
Intervention
Hyaluronic acid
10 million Bone marrow mesenchimal stem cells
100 million Bone marrow mesenchimal stem cells
Sponsored by
Clinica Universidad de Navarra, Universidad de Navarra
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis, Mesenchimal stem cell, Knee

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females between 50 and 80 year old.
  • Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology).
  • Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).
  • Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.
  • Body mass index between 20 and 35 kg/m2.
  • Ability to follow during the study period.

Exclusion Criteria:

  • Bilateral Osteoarthritis of the Knee requiring treatment in both knees.
  • Previous diagnosis of polyarticular disease.
  • Severe mechanical deformation.
  • Arthroscopy during the previous 6 months.
  • Intraarticular infiltration of hyaluronic acid in the last 6 months.
  • Systemic autoimmune rheumatic disease.
  • Poorly controlled diabetes mellitus.
  • Blood dyscrasias.
  • Immunosuppressive or anticoagulant treatments.
  • Treatment with corticosteroids in the 3 months prior to inclusion in the study.
  • NSAID therapy within 15 days prior to inclusion in the study.
  • Patients with a history of allergy to penicillin or streptomycin.
  • Allergy to hyaluronic acid or poultry proteins.

Sites / Locations

  • Traumatology department. Complejo Hospitalario de Salamanca
  • Orthopaedic and traumatology department. Clínica Universidad de Navarra

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Hialuronic acid

Hyaluronic acid and MSC 10

Hyaluronic acid AND MSC 100

Arm Description

Single intraarticular injection of Hyaluronic acid (Hyal One)

Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells

Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells

Outcomes

Primary Outcome Measures

Baseline Visual analogue scale (VAS)
Baseline Visual analogue scale (VAS)
Baseline value of knee injury and osteoarthritis outcome score (Koos).
Prior to the intervention on day 1 value of knee injury and osteoarthritis outcome score (Koos).
Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).
Prior to the intervention on day 1 Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).
Baseline SF-36 value
Prior to the intervention on day 1 SF-36 value
Baseline euroquol 5D value
Pretreatment euroquol 5D value
Baseline Lequesne index
Prior to the intervention on day 1 Lequesne index
Baseline femorotibial distance
Prior to the intervention femoritibial distance on rosenberg x-ray view
Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events
During the follow up
Visual analogue scale (VAS) at on month
Visual analogue scale (VAS) at on month
Visual analogue scale (VAS) at 3 months
Visual analogue scale (VAS) at 3 months
Visual analogue scale (VAS) at 6 months
Visual analogue scale (VAS) at 6 months
Visual analogue scale (VAS) at 12 months
Visual analogue scale (VAS) at 12 months
Value of knee injury and osteoarthritis outcome score (Koos) at 1 month
Value of knee injury and osteoarthritis outcome score (Koos) at 1 month
Value of knee injury and osteoarthritis outcome score (Koos) at 3 month
Value of knee injury and osteoarthritis outcome score (Koos) at 3 month
Value of knee injury and osteoarthritis outcome score (Koos) at 6 month
Value of knee injury and osteoarthritis outcome score (Koos) at 6 month
Value of knee injury and osteoarthritis outcome score (Koos) at 12 months
Value of knee injury and osteoarthritis outcome score (Koos) at 12 months
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months
SF-36 value at 1 month
SF-36 value
SF 36 value at 3 months
SF 36 value at 3 months
SF 36 value at 6 months
SF 36 value at 6 months
SF 36 value at 12 months
SF 36 value at 12 months
Euroquol 5D value at 1 month
Euroquol 5D value at 1 month
Euroquol 5D value at 3 months
Euroquol 5D value at 3 months
Euroquol 5D value at 6 months
Euroquol 5D value at 6 months
Euroquol 5D value at 12 months
Euroquol 5D value at 12 months
Lequesne index at 1 month
Lequesne index at 1 month
Lequesne index at 3 months
Lequesne index at 3 months
Lequesne index at 6 months
Lequesne index at 6 months
Lequesne index at 12 months
Lequesne index at 12 months
Femorotibial distance at 6 months
Femorotibial distance at 6 months
Femorotibial distance at 12 months
Femorotibial distance at 12 months
Baseline MRI WORMS protocol
Prior to the intervention MRI WORMS protocol
MRI WORMS protocol score at 6 months
MRI WORMS protocol score at 6 months
MRI WORMS protocol score at 12 months
MRI WORMS protocol score at 12 months

Secondary Outcome Measures

Full Information

First Posted
November 12, 2013
Last Updated
October 23, 2017
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
search

1. Study Identification

Unique Protocol Identification Number
NCT02123368
Brief Title
Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells
Official Title
Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinica Universidad de Navarra, Universidad de Navarra

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological) of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients with knee osteoarthritis. Patients and methods Clinical trial phase I- II, randomized , multicenter , with three treatment arms and 10 patients for each group. The investigators compare the intraarticular injection of hialuronic acid against the administration of two different doses of mesenchymal stem cells with hialuronic acid according to the following scheme: Group A: intra-articular injection of hyaluronic acid (Hyalone®). Single dose. Group B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection Hiaurónico Acid ( Hyalone®). Group C : High dose of MSCs. Intra-articular injection of 100 million autologous mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection Hiaurónico Acid (Hyalone®). The primary endpoint is safety and feasibility. The investigators registered the occurrence of complications and / or adverse effects during the study. In addition the investigators assess the response to intra-articular infusion of CMM analyzing the following parameters: Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS. Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space. Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the number location of the lesions , cartilage thickness , signal intensity , subchondral bone alteration , volume and WORMS and dGEMRIC protocols.
Detailed Description
Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological) of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients with knee osteoarthritis. Patients and methods Clinical trial phase I- II, randomized , multicenter , with three treatment arms and 10 patients for each group. The investigators compare the intraarticular injection of hialuronic acid against the administration of two different doses of mesenchymal stem cells with hialuronic acid according to the following scheme: Group A: intra-articular injection of hyaluronic acid (Hyalone®). Single dose. Group B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection Hiaurónico Acid ( Hyalone®). Group C : High dose of MSCs. Intra-articular injection of 100 million autologous mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection Hiaurónico Acid (Hyalone®). The autologous mesenchymal stem cells are obtained from the iliac crest and cultured ex vivo under local anesthesia and sedation. The primary endpoint is safety and feasibility. The investigators registered the occurrence of complications and / or adverse effects during the study. In addition the investigators assess the response to intra-articular infusion of CMM analyzing the following parameters: Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS. Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space. Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the number location of the lesions , cartilage thickness , signal intensity , subchondral bone alteration , volume and WORMS and dGEMRIC protocols. All patients met the following inclusion and exclusion criteria: Inclusion Criteria: Males and females between 50 and 80 year old. Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology). Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS). Radiological Classification: Kellgren-Lawrence scale greater or equal to 2. Body mass index between 20 and 35 kg/m2. Ability to follow during the study period. Exclusion Criteria: Bilateral Osteoarthritis of the Knee requiring treatment in both knees. Previous diagnosis of polyarticular disease. Severe mechanical deformation. Arthroscopy during the previous 6 months. Intraarticular infiltration of hyaluronic acid in the last 6 months. Systemic autoimmune rheumatic disease. Poorly controlled diabetes mellitus. Blood dyscrasias. Immunosuppressive or anticoagulant treatments. Treatment with corticosteroids in the 3 months prior to inclusion in the study. NSAID therapy within 15 days prior to inclusion in the study. Patients with a history of allergy to penicillin or streptomycin. Allergy to hyaluronic acid or poultry proteins.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Osteoarthritis, Mesenchimal stem cell, Knee

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hialuronic acid
Arm Type
Active Comparator
Arm Description
Single intraarticular injection of Hyaluronic acid (Hyal One)
Arm Title
Hyaluronic acid and MSC 10
Arm Type
Active Comparator
Arm Description
Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
Arm Title
Hyaluronic acid AND MSC 100
Arm Type
Active Comparator
Arm Description
Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells
Intervention Type
Drug
Intervention Name(s)
Hyaluronic acid
Other Intervention Name(s)
HyalOne
Intervention Description
Single intraarticular injection of Hyaluronic acid (Hyal One)
Intervention Type
Biological
Intervention Name(s)
10 million Bone marrow mesenchimal stem cells
Intervention Description
10 million of Bone marrow mesenchimal stem cells
Intervention Type
Biological
Intervention Name(s)
100 million Bone marrow mesenchimal stem cells
Intervention Description
100 million of Bone marrow mesenchimal stem cells
Primary Outcome Measure Information:
Title
Baseline Visual analogue scale (VAS)
Description
Baseline Visual analogue scale (VAS)
Time Frame
prior to the initial dose on day 1
Title
Baseline value of knee injury and osteoarthritis outcome score (Koos).
Description
Prior to the intervention on day 1 value of knee injury and osteoarthritis outcome score (Koos).
Time Frame
Prior to the intervention on day 1
Title
Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).
Description
Prior to the intervention on day 1 Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).
Time Frame
Prior to the intervention on day 1
Title
Baseline SF-36 value
Description
Prior to the intervention on day 1 SF-36 value
Time Frame
Prior to the intervention on day 1
Title
Baseline euroquol 5D value
Description
Pretreatment euroquol 5D value
Time Frame
Prior to the intervention on day 1
Title
Baseline Lequesne index
Description
Prior to the intervention on day 1 Lequesne index
Time Frame
Prior to the intervention on day 1
Title
Baseline femorotibial distance
Description
Prior to the intervention femoritibial distance on rosenberg x-ray view
Time Frame
Prior to the intervention
Title
Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events
Description
During the follow up
Time Frame
Follow up
Title
Visual analogue scale (VAS) at on month
Description
Visual analogue scale (VAS) at on month
Time Frame
1 month
Title
Visual analogue scale (VAS) at 3 months
Description
Visual analogue scale (VAS) at 3 months
Time Frame
3 months
Title
Visual analogue scale (VAS) at 6 months
Description
Visual analogue scale (VAS) at 6 months
Time Frame
6 months
Title
Visual analogue scale (VAS) at 12 months
Description
Visual analogue scale (VAS) at 12 months
Time Frame
12 months
Title
Value of knee injury and osteoarthritis outcome score (Koos) at 1 month
Description
Value of knee injury and osteoarthritis outcome score (Koos) at 1 month
Time Frame
1 month
Title
Value of knee injury and osteoarthritis outcome score (Koos) at 3 month
Description
Value of knee injury and osteoarthritis outcome score (Koos) at 3 month
Time Frame
3 Months
Title
Value of knee injury and osteoarthritis outcome score (Koos) at 6 month
Description
Value of knee injury and osteoarthritis outcome score (Koos) at 6 month
Time Frame
6 months
Title
Value of knee injury and osteoarthritis outcome score (Koos) at 12 months
Description
Value of knee injury and osteoarthritis outcome score (Koos) at 12 months
Time Frame
12 months
Title
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month
Description
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month
Time Frame
1 month
Title
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month
Description
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month
Time Frame
3 months
Title
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month
Description
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month
Time Frame
6 months
Title
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months
Description
Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months
Time Frame
12 months
Title
SF-36 value at 1 month
Description
SF-36 value
Time Frame
1 month
Title
SF 36 value at 3 months
Description
SF 36 value at 3 months
Time Frame
3 months
Title
SF 36 value at 6 months
Description
SF 36 value at 6 months
Time Frame
6 months
Title
SF 36 value at 12 months
Description
SF 36 value at 12 months
Time Frame
12 months
Title
Euroquol 5D value at 1 month
Description
Euroquol 5D value at 1 month
Time Frame
1 MOnth
Title
Euroquol 5D value at 3 months
Description
Euroquol 5D value at 3 months
Time Frame
3 months
Title
Euroquol 5D value at 6 months
Description
Euroquol 5D value at 6 months
Time Frame
6 months
Title
Euroquol 5D value at 12 months
Description
Euroquol 5D value at 12 months
Time Frame
12 months
Title
Lequesne index at 1 month
Description
Lequesne index at 1 month
Time Frame
1 month
Title
Lequesne index at 3 months
Description
Lequesne index at 3 months
Time Frame
3 months
Title
Lequesne index at 6 months
Description
Lequesne index at 6 months
Time Frame
6 months
Title
Lequesne index at 12 months
Description
Lequesne index at 12 months
Time Frame
12 months
Title
Femorotibial distance at 6 months
Description
Femorotibial distance at 6 months
Time Frame
6 months
Title
Femorotibial distance at 12 months
Description
Femorotibial distance at 12 months
Time Frame
12 months
Title
Baseline MRI WORMS protocol
Description
Prior to the intervention MRI WORMS protocol
Time Frame
Prior to the intervention
Title
MRI WORMS protocol score at 6 months
Description
MRI WORMS protocol score at 6 months
Time Frame
6 months
Title
MRI WORMS protocol score at 12 months
Description
MRI WORMS protocol score at 12 months
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females between 50 and 80 year old. Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology). Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS). Radiological Classification: Kellgren-Lawrence scale greater or equal to 2. Body mass index between 20 and 35 kg/m2. Ability to follow during the study period. Exclusion Criteria: Bilateral Osteoarthritis of the Knee requiring treatment in both knees. Previous diagnosis of polyarticular disease. Severe mechanical deformation. Arthroscopy during the previous 6 months. Intraarticular infiltration of hyaluronic acid in the last 6 months. Systemic autoimmune rheumatic disease. Poorly controlled diabetes mellitus. Blood dyscrasias. Immunosuppressive or anticoagulant treatments. Treatment with corticosteroids in the 3 months prior to inclusion in the study. NSAID therapy within 15 days prior to inclusion in the study. Patients with a history of allergy to penicillin or streptomycin. Allergy to hyaluronic acid or poultry proteins.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
José Lamo-Espinosa, MD
Organizational Affiliation
Clinica Universidad de Navarra
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Felipe Prosper, MD PhD
Organizational Affiliation
Clinica Universidad de Navarra
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Juan Blanco, MD PhD
Organizational Affiliation
University of Salamanca
Official's Role
Principal Investigator
Facility Information:
Facility Name
Traumatology department. Complejo Hospitalario de Salamanca
City
Salamanca
State/Province
Castilla y León
ZIP/Postal Code
37007
Country
Spain
Facility Name
Orthopaedic and traumatology department. Clínica Universidad de Navarra
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
34895259
Citation
Lamo-Espinosa JM, Prosper F, Blanco JF, Sanchez-Guijo F, Alberca M, Garcia V, Gonzalez-Vallinas M, Garcia-Sancho J. Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis. J Transl Med. 2021 Dec 11;19(1):506. doi: 10.1186/s12967-021-03160-2.
Results Reference
derived
PubMed Identifier
30064455
Citation
Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Molto F, Nunez-Cordoba JM, Lopez-Elio S, Andreu E, Sanchez-Guijo F, Aquerreta JD, Bondia JM, Valenti-Azcarate A, Del Consuelo Del Canizo M, Villaron EM, Valenti-Nin JR, Prosper F. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2018 Jul 31;16(1):213. doi: 10.1186/s12967-018-1591-7.
Results Reference
derived
PubMed Identifier
27565858
Citation
Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Molto F, Nunez-Cordoba JM, Sanchez-Echenique C, Bondia JM, Aquerreta JD, Andreu EJ, Ornilla E, Villaron EM, Valenti-Azcarate A, Sanchez-Guijo F, Del Canizo MC, Valenti-Nin JR, Prosper F. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016 Aug 26;14(1):246. doi: 10.1186/s12967-016-0998-2.
Results Reference
derived
Links:
URL
http://www.cun.es/actualidad/noticias/celulas-madre-osea-artrosis-rodilla
Description
University clinic of navarre trial information

Learn more about this trial

Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells

We'll reach out to this number within 24 hrs